Guardant360® CDx is the first companion diagnostic to be approved in Japan to identify ESR1 mutations in patients with hormone receptor-positive, HER2-negative breast cancer for treatment with ...
ROLLE, Switzerland and TOKYO, Oct. 16, 2025 /PRNewswire/ -- A.D.A.M. Innovations, Japan's leading private genetic testing company, and SOPHiA GENETICS (SOPH) (Nasdaq: SOPH), an AI technology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback